Loading compound...

Epidermal growth factor receptor erbB1 inhibitor

Icotinib is a small molecule drug currently being studied in clinical trials. It works by inhibiting the epidermal growth factor receptor erbB1. It is being researched for various types of cancer, including lung cancer and breast cancer, as well as psoriasis.

How it worksIcotinib works by blocking a specific protein called the epidermal growth factor receptor erbB1, which can help stop the growth of certain cancer cells.

Used for
Lung cancerNon-small cell lung carcinomaLung adenocarcinomaBreast cancerEsophageal cancerGeneral neoplasms (cancer)Psoriasis
Conditions
Lung cancerBreast cancerEsophageal cancerPsoriasis
Class
Small moleculeErbB1 inhibitorEpidermal growth factor receptor erbB1 inhibitorImmune systemRespiratory system

How to take

This drug is currently in the research phase (Phase 3) and is not yet widely available for general use.

Talk to your doctor

Questions to ask

  • ·Is Icotinib appropriate for my type of cancer?
  • ·What are the potential risks of participating in an Icotinib clinical trial?
  • ·How does Icotinib interact with my current medications?

Educational summary derived from FDA labeling, AI-assisted. Not medical advice — consult a healthcare professional. Updated 2026-04-26.